Tecan Group AG (SWX:TECN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 1.97B -9.7% |
| Revenue (ttm) | 882.48M -5.5% |
| Net Income | -110.65M |
| EPS | -8.74 |
| Shares Out | 12.53M |
| PE Ratio | n/a |
| Forward PE | 25.50 |
| Dividend | 3.00 (1.91%) |
| Ex-Dividend Date | Apr 17, 2026 |
| Volume | 11,847 |
| Open | 154.60 |
| Previous Close | 156.80 |
| Day's Range | 154.50 - 157.40 |
| 52-Week Range | 110.60 - 177.50 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 165.48 (+6.01%) |
| Earnings Date | Aug 11, 2026 |
About Tecan Group AG
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for TECN stock is "Buy." The 12-month stock price target is CHF 165.48, which is an increase of 6.01% from the latest price.
News
Tecan Group Reports Steady Q1 Growth; Maintains 2026 Financial Guidance
Tecan Group Reports Steady Q1 Growth; Maintains 2026 Financial Guidance
Tecan Group AG Earnings release: Q1 2026
Tecan Group AG released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Tecan price target lowered to CHF 138 from CHF 148 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Tecan (TCHBF) to CHF 138 from CHF 148 and keeps a Hold rating on the shares.
Tecan price target lowered to CHF 136 from CHF 137 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Tecan (TCHBF) to CHF 136 from CHF 137 and keeps an Equal Weight rating on the shares.
Tecan price target lowered to CHF 148 from CHF 165 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Tecan (TCHBF) to CHF 148 from CHF 165 and keeps a Hold rating on the shares.
Tecan Group AG Earnings Call Transcript: H2 2025
2025 saw a slight sales decline and a net loss due to impairment, but strong cash flow and a robust order book support a stable dividend. The Rewire program targets CHF 1 billion sales and 20% EBITDA by 2028, with gradual market recovery and operational improvements expected.
Tecan Group AG Earnings release: H2 2025
Tecan Group AG released its H2 2025 earnings on March 16, 2026, summarizing the period's financial results.
Tecan Group AG Annual report: H2 2025
Tecan Group AG has published its H2 2025 annual report on March 16, 2026.
Tecan Group AG Slides: H2 2025
Tecan Group AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 16, 2026.
Tecan price target lowered to CHF 137 from CHF 142 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Tecan (TCHBF) to CHF 137 from CHF 142 and keeps an Equal Weight rating on the shares.
Tecan upgraded to Market Perform from Underperform at Bernstein
Bernstein upgraded Tecan (TCHBF) to Market Perform from Underperform with a CHF 156 price target The firm says the company is now better positioned for a recovery in life sciences…
Tecan Group AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
A new CEO is driving a transformation program focused on portfolio discipline, commercial and operational excellence to reignite growth. Automation and AI are key market drivers, with new products and geographic expansion supporting a gradual recovery and midterm growth targets.
Tecan Group AG Slides: 44th Annual J.P. Morgan Healthcare Conference
Tecan Group AG has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
Tecan price target raised to CHF 205 from CHF 200 at Berenberg
Berenberg analyst Harry Gillis raised the firm’s price target on Tecan (TCHBF) to CHF 205 from CHF 200 and keeps a Buy rating on the shares.
Tecan Group AG Earnings release: H2 2025
Tecan Group AG released its H2 2025 earnings on January 9, 2026, summarizing the period's financial results.
Tecan price target lowered to CHF 142 from CHF 160 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Tecan (TCHBF) to CHF 142 from CHF 160 and keeps an Equal Weight rating on the shares.
Tecan price target lowered to CHF 165 from CHF 170 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on Tecan (TCHBF) to CHF 165 from CHF 170 and keeps a Hold rating on the shares. Published first on…
Tecan price target lowered to CHF 170 from CHF 177 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on Tecan (TCHBF) to CHF 170 from CHF 177 and keeps a Hold rating on the shares. Published first on…
Tecan Group AG Earnings release: Q3 2025
Tecan Group AG released its Q3 2025 earnings on October 13, 2025, summarizing the period's financial results.
Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confir...
Tecan price target lowered to CHF 177 from CHF 190 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on Tecan (TCHBF) to CHF 177 from CHF 190 and keeps a Hold rating on the shares. Published first on…
Tecan price target lowered to CHF 210 from CHF 220 at Berenberg
Berenberg lowered the firm’s price target on Tecan (TCHBF) to CHF 210 from CHF 220 and keeps a Buy rating on the shares.
Tecan price target lowered to CHF 168 from CHF 176 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Tecan (TCHBF) to CHF 168 from CHF 176 and keeps an Equal Weight rating on the shares. Published first…
Tecan Group AG Earnings Call Transcript: H1 2025
Revenue and adjusted EBITDA for H1 2025 met expectations amid challenging markets, with strong clinical diagnostics and improved gross margin offsetting declines in China and Partnering. Full-year guidance is maintained, with tariff and FX risks mitigated by cost controls and operational flexibility.
Tecan Group AG Quarterly report: H1 2025
Tecan Group AG has published its H1 2025 quarterly earnings report on August 12, 2025.